Key result
Pretreatment with oral anticoagulants plus aspirin reduced the median number of P-selectin-positive platelets before coronary angioplasty compared to aspirin alone (28 vs. 54, P=0.018).
Why the study?
Does pretreatment with oral anticoagulants in addition to aspirin reduce platelet activation in patients undergoing coronary angioplasty?
RCT (n=52)
randomized
Does pretreatment with oral anticoagulants in addition to aspirin reduce platelet activation in patients undergoing coronary angioplasty?
Absolute Event Rate: 28% vs 54%
p-value: p=0.018
Pretreatment with oral anticoagulants reduces platelet activation prior to coronary angioplasty, providing a mechanistic basis for the reduction in acute complications seen in the BAAS trial.
Supports combined anticoagulant-aspirin pretreatment to lower periprocedural platelet activation; extends mechanistic basis for BAAS trial benefits.
BACKGROUND: Platelet activation plays a major role in acute vessel closure after coronary angioplasty. In the randomized Balloon Angioplasty and Anticoagulation Study (BAAS), pretreatment with oral anticoagulants in addition to aspirin resulted in a 47% reduction of acute complications as compared with aspirin alone. This result may suggest a direct effect of oral anticoagulants on platelet activation. METHODS AND RESULTS: Patients were randomized to aspirin alone (group A, n = 26) or to aspirin plus oral anticoagulants started one week before angioplasty (group B, n = 26). Platelet response tests were performed 1 hour before (baseline) and 1 hour after intervention and on day 1. Platelet activation was measured by flow cytometry, as the number of antibody-positive platelets per 10,000 counted. Platelet function was evaluated with use of the PFA-100 analyzer. In group B, the median number of P-selectin-positive platelets was lower before (28 vs. 54, P = 0.018) and after (13 vs. 24, P = 0.377) angioplasty than in group A. Also the median decrease in the number of P-selectin-positive platelets during angioplasty was lower in group B (delta = 4) than in group A (delta = 30, P = 0.022). No further significant change was observed in platelet activation on day 1 in the two groups. The ability of platelets to become stimulated as measured with the PFA-100 analyzer was not affected by oral anticoagulants. CONCLUSIONS: Pretreatment with oral anticoagulants resulted in less activated platelets before and after coronary angioplasty, which is in agreement with its clinical effect of reducing procedural complications. Platelet function was not affected by oral anticoagulants.
No takes yet. Share an insight, caveat, or question.
Gerritsen et al. (2002) conducted an RCT in Coronary angioplasty (n=52). Oral anticoagulants plus aspirin vs. Aspirin alone was evaluated on Median number of P-selectin-positive platelets before angioplasty (p=0.018). Pretreatment with oral anticoagulants plus aspirin reduced the median number of P-selectin-positive platelets before coronary angioplasty compared to aspirin alone (28 vs. 54, P=0.018).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: